Product logins

Find logins to all Clarivate products below.


Pemphigus Vulgaris – Epidemiology – Extrapolated Worldwide Coverage

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key pemphigus vulgaris patient populations, covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download.

Use the Extrapolated Worldwide Coverage dashboard to do the following:

  • View 10-year forecasts of the diagnosed prevalent cases for all 171 countries, stratified by region and World Bank income status.
  • Aggregate country-level estimates into region-level estimates according to user preference or as required by regulators for orphan drug designations.
  • Visualize global correlations between disease risk or size of patient population and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
  • Generate and export global heat maps of disease risk or size of patient population.

The Extrapolated Worldwide Coverage dashboard is available as an Excel file in the Downloads section at the top right of this page. It is available for purchase by clients with subscriptions to all 45 countries covered by Clarivate Epidemiology. For subscription and entitlement queries, please contact Clarivate.support@clarivate.com.

Related Market Assessment Reports

Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 853 currently available and novel biosimilar products, detailing…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric ADHD (US)
ADHD is a common pediatric neurodevelopmental disorder, with diagnosis rates supported by increased awareness and routine screening; however, symptoms often persist into adulthood. Longacting…
Report
Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC) continues to evolve with the expanding role of immune checkpoint inhibitors and novel targeted therapies. The…
Report
Multiple Sclerosis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is crowded and competitive, as TG Therapeutics / Neuraxpharm’s Briumvi (ublituximab), Novartis’s Kesimpta (ofatumumab…